fda nod sought for blood substitute evanston ill northfield laboratories inc said it plans to seek possible food and drug administration approval for its blood substitute polyheme even though the product has been linked to a higher death rate in a clinical study than the death rate among patients receiving donor blood the company whose only product is polyheme said its "singular focus" for fiscal will be to file with the federal agency for possible marketing approval of the blood substitute the company said it hopes to gain approval for polyheme in situations where donor blood isnt available in the clinical trial trauma patients across the u s were randomly assigned to receive either polyheme or donated blood the studys conclusion was that people or died among patients receiving polyheme versus who died or among those receiving donor blood the deaths were measured at days after the initial accident leading to hospitalization 
